KR102717594B1 - 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제 - Google Patents

혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제 Download PDF

Info

Publication number
KR102717594B1
KR102717594B1 KR1020207007344A KR20207007344A KR102717594B1 KR 102717594 B1 KR102717594 B1 KR 102717594B1 KR 1020207007344 A KR1020207007344 A KR 1020207007344A KR 20207007344 A KR20207007344 A KR 20207007344A KR 102717594 B1 KR102717594 B1 KR 102717594B1
Authority
KR
South Korea
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007344A
Other languages
English (en)
Korean (ko)
Other versions
KR20200054199A (ko
Inventor
지오반니 시안체타
타오 리우
아닐 쿠마 파다이아나
지후아 수이
첸웨이 카이
다웨이 쿠이
징징 지
Original Assignee
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지오스 파마슈티컬스 아이엔씨. filed Critical 아지오스 파마슈티컬스 아이엔씨.
Priority to KR1020237028222A priority Critical patent/KR102764124B1/ko
Publication of KR20200054199A publication Critical patent/KR20200054199A/ko
Application granted granted Critical
Publication of KR102717594B1 publication Critical patent/KR102717594B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207007344A 2017-08-15 2018-08-15 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제 Active KR102717594B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237028222A KR102764124B1 (ko) 2017-08-15 2018-08-15 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/097496 2017-08-15
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028222A Division KR102764124B1 (ko) 2017-08-15 2018-08-15 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제

Publications (2)

Publication Number Publication Date
KR20200054199A KR20200054199A (ko) 2020-05-19
KR102717594B1 true KR102717594B1 (ko) 2024-10-14

Family

ID=63524352

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207007344A Active KR102717594B1 (ko) 2017-08-15 2018-08-15 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제
KR1020207007346A Active KR102642408B1 (ko) 2017-08-15 2018-08-15 피루브산 키나아제 조절제 및 이의 용도
KR1020237028222A Active KR102764124B1 (ko) 2017-08-15 2018-08-15 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020207007346A Active KR102642408B1 (ko) 2017-08-15 2018-08-15 피루브산 키나아제 조절제 및 이의 용도
KR1020237028222A Active KR102764124B1 (ko) 2017-08-15 2018-08-15 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제

Country Status (34)

Country Link
US (8) US11364240B2 (enExample)
EP (4) EP3668512B1 (enExample)
JP (5) JP7301040B2 (enExample)
KR (3) KR102717594B1 (enExample)
CN (3) CN111032045B (enExample)
AU (4) AU2018316588B2 (enExample)
BR (2) BR112020003254A2 (enExample)
CA (1) CA3072455A1 (enExample)
CL (1) CL2020000375A1 (enExample)
CO (2) CO2020002961A2 (enExample)
CR (1) CR20200123A (enExample)
CY (1) CY1124953T1 (enExample)
DK (2) DK3668512T3 (enExample)
EC (1) ECSP20018487A (enExample)
ES (3) ES2944545T3 (enExample)
FI (1) FI3668512T3 (enExample)
HR (2) HRP20230452T1 (enExample)
HU (2) HUE061910T2 (enExample)
IL (3) IL272599B (enExample)
LT (2) LT3668512T (enExample)
MD (1) MD3668513T2 (enExample)
MX (2) MX2020001832A (enExample)
MY (1) MY204421A (enExample)
PE (1) PE20200724A1 (enExample)
PH (1) PH12020500343B1 (enExample)
PL (2) PL3668512T3 (enExample)
PT (2) PT3668512T (enExample)
RS (2) RS62871B1 (enExample)
SG (2) SG11202001353PA (enExample)
SI (2) SI3668513T1 (enExample)
SM (2) SMT202300146T1 (enExample)
TW (3) TWI796353B (enExample)
UA (1) UA126292C2 (enExample)
WO (3) WO2019035864A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000290A1 (en) 2017-03-20 2021-05-07 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11202001353PA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase modulators and use thereof
EP3697354A4 (en) 2017-10-20 2021-06-30 The Regents of The University of Michigan EYE DISEASE COMPOSITIONS AND METHODS
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
CA3129829A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
CN114008147B (zh) * 2019-06-26 2023-05-02 日产化学株式会社 电荷传输性清漆
BR112022004715A2 (pt) 2019-09-19 2022-06-14 Forma Therapeutics Inc Composições de ativação de piruvato quinase r (pkr)
EP4185293A4 (en) * 2020-07-21 2025-01-15 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
US11566030B2 (en) 2021-02-08 2023-01-31 Global Blood Therapeutics, Inc. Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240409542A1 (en) * 2021-09-30 2024-12-12 Sitryx Therapeutics Limited Novel compounds
EP4433057A1 (en) * 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
WO2024238659A1 (en) 2023-05-15 2024-11-21 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
HK1049154A1 (zh) 1999-07-30 2003-05-02 Abbott Gmbh & Co. Kg 作为酪氨酸激酶抑制剂的2-吡唑啉-5-酮
CA2381581A1 (en) 1999-09-04 2001-03-15 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2011529066A (ja) * 2008-07-23 2011-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド 三環式ピラゾロピリジンキナーゼ阻害剤
US8420649B2 (en) * 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
CA3041868C (en) 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
CA2820408C (en) 2010-12-06 2018-03-06 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151452A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
PH12017501176B1 (en) 2011-05-03 2023-03-08 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
WO2012151448A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
EP2734520B1 (en) * 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
EP2917207A1 (en) 2012-11-08 2015-09-16 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
CN105008363A (zh) * 2013-01-30 2015-10-28 拜耳医药股份公司 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪
HK1220610A1 (zh) 2013-03-13 2017-05-12 弗拉特利发现实验室有限责任公司 哒嗪酮化合物和用於治疗囊肿状纤维化的方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
AR112690A1 (es) 2017-08-15 2019-11-27 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3652184A1 (en) 2017-08-15 2020-05-20 AbbVie Inc. Macrocyclic mcl-1 inhibitors and methods of use
SG11202001353PA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase modulators and use thereof
CA3129829A1 (en) * 2019-02-13 2020-08-20 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human Mutation, 2008, 30, 446-453.

Also Published As

Publication number Publication date
TW201919631A (zh) 2019-06-01
US11872225B2 (en) 2024-01-16
DK3668512T3 (da) 2023-05-22
CR20200123A (es) 2020-06-29
IL292530B2 (en) 2023-06-01
EP3668512A1 (en) 2020-06-24
TWI790271B (zh) 2023-01-21
US20210077490A1 (en) 2021-03-18
US20200206225A1 (en) 2020-07-02
KR102764124B1 (ko) 2025-02-05
US11040036B2 (en) 2021-06-22
US20220233541A1 (en) 2022-07-28
PT3668513T (pt) 2022-01-21
LT3668512T (lt) 2023-06-12
RU2020110573A3 (enExample) 2021-12-24
HUE061910T2 (hu) 2023-08-28
IL272597A (en) 2020-03-31
JP2023027276A (ja) 2023-03-01
MX2020001833A (es) 2020-07-22
CN111032046A (zh) 2020-04-17
EP4026838A1 (en) 2022-07-13
BR112020003254A2 (pt) 2020-10-27
EP3668881B1 (en) 2023-10-04
WO2019035863A8 (en) 2019-03-28
IL272597B (en) 2022-06-01
WO2019035864A8 (en) 2019-03-28
IL292530A (en) 2022-06-01
WO2019035863A1 (en) 2019-02-21
SI3668512T1 (sl) 2023-06-30
HRP20230452T1 (hr) 2023-07-21
JP2023052478A (ja) 2023-04-11
JP2024147805A (ja) 2024-10-16
WO2019035864A1 (en) 2019-02-21
JP7275107B2 (ja) 2023-05-17
CN111032046B (zh) 2023-09-26
DK3668513T3 (da) 2022-01-10
US12133853B2 (en) 2024-11-05
UA126292C2 (uk) 2022-09-14
SG11202001262QA (en) 2020-03-30
WO2019035865A8 (en) 2019-03-28
JP7301040B2 (ja) 2023-06-30
AU2023202772A1 (en) 2023-05-18
CN117186119A (zh) 2023-12-08
US20230226055A1 (en) 2023-07-20
TWI823580B (zh) 2023-11-21
FI3668512T3 (fi) 2023-05-12
IL272599A (en) 2020-03-31
PH12020500343B1 (en) 2024-02-21
JP2020531443A (ja) 2020-11-05
SMT202300146T1 (it) 2023-07-20
MX2020001832A (es) 2020-07-22
KR102642408B1 (ko) 2024-02-28
HUE057178T2 (hu) 2022-04-28
CA3071993A1 (en) 2019-02-21
ES2966825T3 (es) 2024-04-24
KR20200054200A (ko) 2020-05-19
AU2024205818A1 (en) 2024-09-05
ES2944545T3 (es) 2023-06-22
KR20200054199A (ko) 2020-05-19
CO2020002961A2 (es) 2020-04-13
US20250144093A1 (en) 2025-05-08
US11957680B2 (en) 2024-04-16
SI3668513T1 (sl) 2022-04-29
RU2020110573A (ru) 2021-09-16
MY204421A (en) 2024-08-28
RS62871B1 (sr) 2022-02-28
ECSP20018487A (es) 2020-05-29
EP3668881A1 (en) 2020-06-24
CA3072455A1 (en) 2019-02-21
SMT202200023T1 (it) 2022-03-21
AU2018316588A1 (en) 2020-02-20
PT3668512T (pt) 2023-05-22
US20220395503A1 (en) 2022-12-15
CL2020000375A1 (es) 2020-12-11
CO2020002959A2 (es) 2020-04-13
MD3668513T2 (ro) 2022-04-30
PL3668512T3 (pl) 2023-06-19
RS64221B1 (sr) 2023-06-30
JP7530453B2 (ja) 2024-08-07
CN111032045B (zh) 2023-08-15
EP3668513A1 (en) 2020-06-24
LT3668513T (lt) 2022-03-25
TW201920203A (zh) 2019-06-01
PL3668513T3 (pl) 2022-03-21
AU2023202772B2 (en) 2024-05-16
CN111032045A (zh) 2020-04-17
US11590132B2 (en) 2023-02-28
US11364240B2 (en) 2022-06-21
PE20200724A1 (es) 2020-07-21
ES2905100T3 (es) 2022-04-07
JP2020531432A (ja) 2020-11-05
AU2018316587B2 (en) 2023-05-11
US20200207785A1 (en) 2020-07-02
US11464775B2 (en) 2022-10-11
AU2018316587A1 (en) 2020-02-20
EP3668513B1 (en) 2021-11-10
TWI796353B (zh) 2023-03-21
AU2018316588B2 (en) 2023-02-02
IL272599B (en) 2022-08-01
HRP20220039T1 (hr) 2022-04-15
PH12020500343A1 (en) 2021-02-08
CY1124953T1 (el) 2023-01-05
EP3668512B1 (en) 2023-02-15
BR112020003262A2 (pt) 2020-09-01
KR20230127364A (ko) 2023-08-31
TW202323258A (zh) 2023-06-16
SG11202001353PA (en) 2020-03-30
WO2019035865A1 (en) 2019-02-21
US20210130371A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
KR102717594B1 (ko) 혈액 장애의 치료에 사용하기 위한 피루브산 키나아제 활성화제
HK40077435A (en) Pyruvate kinase activators for use in treating blood disorders
CA3071993C (en) Thiazolo(5',4':4,5)pyrrolo(2,3-d)pyridazine-5-one derivatives and pharmaceutical compositions thereof useful as pyruvate kinase activators for use in treating blood disorders
HK40030323B (en) Pyruvate kinase activators for use in treating blood disorders
EA042084B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови
EA046698B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230520

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231206

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240712

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241010

End annual number: 3

Start annual number: 1

PG1601 Publication of registration